4basebio Plc – Leadership Changes

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF
THE MARKET ABUSE REGULATION (EU) 596/2014 AS IT FORMS PART OF UK DOMESTIC LAW BY
VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018.

10 February 2026

4basebio PLC

(«4basebio» or the «Company»)

Leadership Changes

Cambridge, UK, 10 February 2026 – 4basebio PLC (AIM: 4BB), an innovation driven
biotechnology company enabling and accelerating development of advanced therapy
medicinal products (ATMPs) through its high performant GMP-grade synthetic DNA
products, announces that Dr Amy Walker has been appointed as Chief Executive
Officer, succeeding Dr Heikki Lanckriet, Founder of the Company.

After six years in the role, Heikki has stepped down as CEO in order to lead a
newly formed entity which will be focussed on advancing the Hermes nanoparticle
platform into the clinic. The Board and Executive Leadership team determined
that Amy, with her deep knowledge of the company and commercially-focussed
skillset and experience, is the right candidate to succeed Heikki as the Company
prepares for accelerated commercial growth. Heikki will remain on the Board and
will also continue to support the Company’s scientific and technical leadership.
David Roth will join Heikki in the newly formed entity and will step down as
Chief Financial Officer and as a Director, following an orderly handover period.

Amy has been with the Company for more than five years most recently serving as
Chief Operating Officer. She has played a key role in scaling 4basebio’s GMP
manufacturing capabilities, strengthening direct engagement with top-tier
biopharma customers and supporting the Company’s growth operationally and
strategically. As Chief Executive Officer, Amy will lead an accelerated
commercial growth strategy, focusing on deepening penetration of the synthetic
DNA market as customers increasingly seek alternatives to plasmid DNA, and
building on the Company’s recent GMP milestone to support clinical programmes in
cell and gene therapy and vaccine development.

Since the Company’s formation in 2020, Heikki has been responsible for leading
4basebio as it scaled its synthetic DNA technology from concept to clinic, built
a global customer base and stewarded 4basebio in building its high-quality
investor base.

This leadership change comes at a time when the Company enters an expected
period of accelerated commercial growth in 2026 following a successful 2025.
4basebio has top tier pharma clients in the clinic and a strong and growing
pipeline. The trend of drug development companies transitioning from plasmid DNA
to synthetic DNA and RNA continues to gain traction and supports the Company’s
commercial momentum, and we are pleased to have Amy at the helm of this exciting
phase of the Company’s development.

Dr Manja Boerman, Executive Chair of 4basebio, commented: «4basebio’s GMP
synthetic DNA manufacturing services help accelerate development timelines for
cell and gene therapies and vaccines and offer superior safety and efficacy
compared with plasmid DNA, two critical factors for clinical success. With GMP
certification for its facility, the Company is now accelerating its focus on
commercial delivery. Amy has invaluable commercial, scientific and technical
expertise and has spearheaded building out the GMP infrastructure to enable
4basebio to lead this dynamic market. I’m delighted that she will lead the
Company through this critical next phase of development and I look forward to
leveraging my extensive CDMO experience in helping drive the business forward.

«On behalf of the Board and Executive Management Team, I’d like to thank Heikki
for the leadership and vision that has brought the Company to a global market
leadership position. We wish him the best with his new venture and are pleased
he will continue to provide his valued strategic insights and technical support
as he continues to serve on the Board as a technical expert. We will continue to
build out the commercial and operational expertise of the Company and strengthen
the team at this extremely exciting time. The Company would also like to thank
David for his stewardship.»

Dr Amy Walker commented: «I am honoured to be appointed Chief Executive Officer
at a time when 4basebio is poised for significant commercial traction. I look
forward to leading the exceptional 4basebio team, accelerating our commercial
momentum and scaling our GMP grade synthetic DNA offering to support our
customers, while continuing to build long-term value for all stakeholders and,
ultimately, patients.»

Dr Heikki Lanckriet added: «Leading 4basebio has been an exceptional privilege.
Having founded the Company over six years ago and built it to where it is today,
I feel the time is right to hand over the reigns as the Company moves into its
next phase of commercial and operational development. Amy and I have worked
closely together over the past years and she has been instrumental in the growth
and success of 4basebio. Her expertise and judgement will lead the Company to
commercial success and I am delighted that she will succeed me as Chief
Executive Officer. With the Company under excellent stewardship, I am excited to
be able to focus on my passion for entrepreneurship and business creation but I
will continue to support Amy, the Board and the wider team to deliver on the
Company’s goals. Finally, I would like to thank the 4basebio team for their
commitment to the Company. It has been a genuine honour for which I am very
grateful.»

Michael Wasserman, COO of Elevage Medical Technologies, commented: «We are
extremely excited about 4basebio’s move into GMP-grade drug substance
manufacturing and the significant opportunity ahead for synthetic DNA in cell
and gene therapy. Amy has been instrumental in positioning the company to
capture this market inflection-her commercial vision, operational rigour and
deep customer relationships make her the ideal leader to accelerate 4basebio’s
next phase of growth. We look forward to supporting the company as it scales its
differentiated synthetic DNA platform to serve our partners’ innovative
programmes in the clinic.»

This announcement contains inside information for the purposes of Article 7 of
EU Regulation 596/2014 as amended by regulation 11 of the Market Abuse
(Amendment) (EU Exit) Regulations 2019/310.

For further enquiries, please contact:

4basebio PLC                +44 (0)12 2396 7943
Dr Amy Walker, CEO

Cairn Financial Advisers LLP (Nominated Adviser) +44 (0)20 7213 0880
Jo Turner / Sandy Jamieson / Ed Downes

Cavendish Capital Markets Limited (Joint Broker) +44 (0)20 7220 0500
Geoff Nash / Nigel Birks

RBC Capital Markets (Joint Broker) +44 (0)20 7653 4000
Kathryn Deegan / Matthew Coakes
ICR Healthcare (Media and Investor Relations +44 (0)203 707 5700
Mary-Jane Elliott / Jessica Hodgson

Notes to Editors

About 4basebio

4basebio (AIM: 4BB) is an innovation driven life biotechnology company focused
on accelerating the development of advanced therapy medicinal products (ATMPs)
through its high-performance synthetic DNA products and non-viral, cell
targeting nucleic acid delivery platform. The Company’s objective is to become a
market leader in the manufacture and supply of high-quality synthetic DNA
products for research, therapeutic and pharmacological use as well as
development of target specific non-viral vectors for the efficient delivery of
payloads in patients.

About Elevage Medical Technologies

Elevage Medical Technologies is a platform established by Patient Square Capital
and is dedicated to supporting medical technology companies that can
meaningfully improve health outcomes and quality of life for patients. Elevage
provides capital along with deep technical, regulatory, and operational
expertise to companies ranging from advanced clinical development to commercial
acceleration stage. Elevage supports rapidly growing, highly differentiated
companies with paradigm shifting technologies and strives to help build industry
leading medical technologies. To learn more about Elevage, please
visit www.elevagemedical.com (https://eur06.safelinks.protection.outlook.com/?url
=http%3A%2F%2Fwww.elevagemedical.com%2F&data=05%7C02%7Camy.walker%404basebio.com%
7Ca979a93055d1441eb65308de67deae22%7C3ed990fb5c2d4adb90aa512754110215%7C0%7C0%7C6
39062403315365328%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDA
wMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=d4kAzO2l
c55G5qKUpJXwIDIdvOZIde2zs6VuWbt5wU0%3D&reserved=0)

Forward-looking statements

This announcement may contain certain statements about the future outlook for
4basebio.  Although the directors believe their expectations are based on
reasonable assumptions, any statements about future outlook may be influenced by
factors that could cause actual outcomes and results to be materially different.

This information was brought to you by Cision http://news.cision.com